View Total Prescribing Facts OPDIVO® (nivolumab) is indicated for your treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed just after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after three or more traces of systemic therapy that includes autologous HSCT.